ArticlePloS one2025
Prevalence of HIV drug resistance, its correlates and common mutations among people living with HIV failing on ART in northern Uganda: A cross-sectional study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHIV drug resistance (HIVDR) poses a challenge to managing people living with HIV (PLHIV), particularly among those experiencing virological failure (VF). The West-Nile region of Uganda faces HIV treatment challenges and has a high virological failure rate. We estimated the prevalence of HIV drug resistance, described the HIV drug resistance mutations and evaluated the factors associated with HIVDR among PLHIV with virological failure in the West-Nile region of Uganda.
methodsWe conducted a retrospective cross-sectional analysis of HIVDR data in the West-Nile region of Uganda across the 161 health facilities that offer comprehensive Anti-retroviral therapy (ART) services. All PLHIV, regardless of age, who had been on ART for at least one-year, experienced virological failure and underwent an HIVDR test between 1st January 2021-30th December 2023 were included in the study. Demographic and clinical data were extracted from the National HIVDR database. HIVDR was defined as having at least one mutation with a penalty score of ≥15. PLHIV were characterized based on age, gender and clinical history. Logistic regression models determined factors associated with HIVDR with a p-value of <0.05 considered significant.
resultsA total 295 records were analyzed. Of these, majority were female (56.6%) and adults aged ≥20 years (49.2%). The median age was 19 (Inter quartile range [IQR]: 13-41) years, and median duration on ART was 8 (IQR: 5-10) years. Overall, 218 (73.9%) had HIVDR with 66% of subjects having Non-nucleoside reverse transcriptase (NNRTI) mutations. M184V/I (50%), K103N (34%) and TAMS (26%) were the commonest mutations. Resistance to Etravirine (27%) was higher than that of Dolutegravir (12%) and Darunavir (5%). After accounting for gender, age, Nucleoside reverse transcriptase inhibitor (NRTI) anchor drug, ART regimen type and World Health Organization (WHO) clinical stage of the participants; long duration on ART (aOR=; 1.15 95%CI 1.05-1.26 p = 0.003), adolescents failing on first line (aOR=; 3.80 95%CI 1.02-14.08 p = 0.046) and participants failing on 2nd line (aOR=; 3.64 95%CI 1.18-11.21 p = 0.024) as indications for the HIVDR test, and the year of HIVDR sample collection (aOR=; 0.21 95%CI 0.07-0.69 p = 0.010), were independently associated with HIVDR mutations.
conclusionThe study found a high HIVDR prevalence strongly associated with long ART duration which is likely to lead to increased ART treatment failure rates. The high Etravirine resistance and increasing Dolutegravir resistance are likely to complicate future treatment options while low Darunavir resistance makes it a future third-line treatment option. Strengthening routine resistance surveillance, timely VL monitoring, and adherence support are critical to mitigating drug resistance and preserving ART effectiveness among PLHIV in the West-Nile region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.